Compare MNKD & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | PCRX |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.0M |
| IPO Year | 2004 | 2010 |
| Metric | MNKD | PCRX |
|---|---|---|
| Price | $4.25 | $25.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $8.69 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 5.0M | 437.1K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | $348,966,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $35.81 | $6.78 |
| Revenue Next Year | $11.89 | $8.54 |
| P/E Ratio | ★ N/A | $368.86 |
| Revenue Growth | 22.23 | ★ 26.04 |
| 52 Week Low | $2.23 | $18.80 |
| 52 Week High | $6.51 | $27.64 |
| Indicator | MNKD | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 67.57 |
| Support Level | $3.77 | $22.03 |
| Resistance Level | $4.29 | $27.03 |
| Average True Range (ATR) | 0.23 | 0.97 |
| MACD | 0.00 | 0.23 |
| Stochastic Oscillator | 48.42 | 79.94 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.